Sarcopenia, an overlooked diagnosis in kidney transplant recipients

Basit Öğe Kaydı
dc.authoridAkman, Zafer/0000-0002-6317-4417
dc.authoridKaraca, Cebrail/0000-0003-0969-7708
dc.contributor.authorOzcan, Seyda Gul
dc.contributor.authorSonmez, Ozge
dc.contributor.authorAtli, Zeynep
dc.contributor.authorKaraca, Cebrail
dc.contributor.authorAlagoz, Selma
dc.contributor.authorAkman, Zafer
dc.contributor.authorKoroglu, Ali Egemen
dc.date.accessioned2025-03-23T19:25:39Z
dc.date.available2025-03-23T19:25:39Z
dc.date.issued2024
dc.departmentSinop Üniversitesi
dc.description.abstractMost studies of sarcopenia in renal transplant recipients (RTRs) have been hampered by a lack of standardization in the definitions of sarcopenia. In this study, we aimed to investigate the prevalence of sarcopenia and the associated factors in RTRs using the recently proposed criteria of the European Working Group on Sarcopenia in Older People 2018 (EWGSOP2), which included a standardized definition of sarcopenia. We examined 93 consecutive adult RTRs, 46 chronic kidney disease patients, and 46 healthy controls. We assessed the muscle strength with a hand grip test using a dynamometer and with a chair stand test. We used bioimpedance analysis to estimate appendicular skeletal mass using the Sergi formula. Finally, we conducted a 2-minute walking test to assess endurance. Sarcopenia and probable sarcopenia were determined according to the revised criteria of the EWGSOP2. Probable sarcopenia was found in 29 RTR patients (31.2%), of them 14 (15.1%) were diagnosed with sarcopenia. Multivariate logistic regression analysis showed that presence of diabetes mellitus, increased uric acid level, and statin use were risk factors for probable sarcopenia. On the other hand, longer dialysis vintage was a risk factor for sarcopenia in RTRs. We found that probable sarcopenia and sarcopenia were highly prevalent in our relatively young RTRs. We recommend active screening for the presence of sarcopenia in RTRs, especially in the cadaveric ones. Furthermore, caution seems warranted regarding the myopathic side effects in RTRs who use statins.
dc.identifier.doi10.5414/CN111182
dc.identifier.endpage70
dc.identifier.issn0301-0430
dc.identifier.issue2
dc.identifier.pmid38050730
dc.identifier.scopus2-s2.0-85182598140
dc.identifier.scopusqualityQ3
dc.identifier.startpage59
dc.identifier.urihttps://doi.org/10.5414/CN111182
dc.identifier.urihttps://hdl.handle.net/11486/4530
dc.identifier.volume101
dc.identifier.wosWOS:001117848200001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherDustri-Verlag Dr Karl Feistle
dc.relation.ispartofClinical Nephrology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250323
dc.subjectsarcopenia
dc.subjectkidney transplantation
dc.subjectkidney transplant recipients
dc.subjectchronic kidney disease
dc.titleSarcopenia, an overlooked diagnosis in kidney transplant recipients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu